Last reviewed · How we verify
Bromocriptine mesylate tablets
Bromocriptine mesylate is a dopamine D2 receptor agonist that inhibits prolactin secretion and modulates hypothalamic-pituitary function.
Bromocriptine mesylate is a dopamine D2 receptor agonist that inhibits prolactin secretion and modulates hypothalamic-pituitary function. Used for Hyperprolactinemia, Prolactin-secreting pituitary adenoma (prolactinoma), Acromegaly (adjunctive therapy).
At a glance
| Generic name | Bromocriptine mesylate tablets |
|---|---|
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | Dopamine D2 receptor agonist |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Bromocriptine acts as a dopamine agonist at D2 receptors in the tuberoinfundibular pathway, suppressing prolactin release from the anterior pituitary gland. This mechanism makes it effective for treating hyperprolactinemia and prolactin-secreting adenomas. Additionally, dopamine agonism in other brain regions contributes to its effects in movement disorders and metabolic conditions.
Approved indications
- Hyperprolactinemia
- Prolactin-secreting pituitary adenoma (prolactinoma)
- Acromegaly (adjunctive therapy)
- Parkinson's disease (adjunctive therapy)
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Orthostatic hypotension
- Constipation
- Abdominal pain
Key clinical trials
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (PHASE3)
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (PHASE4)
- Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (PHASE1, PHASE2)
- Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets (PHASE1)
- Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects (PHASE4)
- Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy (PHASE2)
- Acute Olanzapine and Lipid Response (PHASE2, PHASE3)
- QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |